UR-9746 and UR-9751 are novel azole derivatives each containing a morpholine ring. They were examined for both in vitro and in vivo activities against Coccidioides immitis. In vitro, UR-9746 and UR-9751 were active, with MICs of 25 and 3.1 g/ml, respectively, against C. immitis Silveira; minimum fungicidal concentrations were >100 g/ml, the highest concentration tested, for both compounds. Antifungal activity in serum showed the desirable characteristic of remaining severalfold above the MIC at all times. Against systemic murine coccidioidomycosis, UR-9746 and UR-9751 prolonged survival at dosages of >10 mg/kg/day and showed increased reduction of infectious burden in the spleens, livers, and lungs of treated mice with escalating dosage. Both compounds lacked observable toxicity and on a milligram-per-kilogram of body weight basis were >10-fold superior to fluconazole in prolonging survival and clearing infection with C. immitis.
The need for improved antifungal therapeutic modalities is evidenced by the ever increasing number of patients with severe fungal infections. The azole compounds have become a mainstay of therapy over the last several years. However, recrudescence of infection and relapse during or after therapy indicate the need for better treatments. UR-9746 and UR-9751 (J. Uriach & Cia, Barcelona, Spain) are two newly described novel fluoridated azole compounds that each contain a morpholine ring (1) . The two compounds are similar in structure and differ by a single hydroxyl group (1) (Fig. 1) .
Both of these compounds have been demonstrated to have good in vitro activity against a variety of fungal pathogens (11) . In addition, these compounds have been preliminarily reported to have in vivo activity superior to that of fluconazole in animal models of vaginal and systemic candidosis (1), systemic and meningeal cryptococcosis (2, 3, 9) , and systemic histoplasmosis (8) . We report in this study the in vitro and in vivo activities of UR-9746 and UR-9751 against Coccidioides immitis.
The in vitro activities of UR-9746, UR-9751, and fluconazole against the Silveira strain of C. immitis were tested by a broth macrodilution method in defined medium (synthetic amino acid medium [fungal]) inoculated with 1,000 arthroconidia/ml (final volume, 3 ml) and incubated statically at ambient temperature (4) (5) (6) (7) . Both the MIC, read after 7 days, and the minimum fungicidal concentration (MFC), read after 7 days, were determined for each drug (4) (5) (6) (7) .
The kinetics of antifungal activity in vivo was studied in uninfected mice. Groups were studied after a single 100-mg/kg of body weight dose or after a treatment regimen identical to that used in the therapeutic study. Sera from two mice were pooled at each time point for bioassay using Candida kefyr SA as the indicator organism as previously described (4) (5) (6) .
A model of systemic coccidioidomycosis was established in 6-week-old female CD-1 mice (mean weight, 24.4 g) by intravenous injection of 232 viable arthroconidia of C. immitis Silveira as described previously (4-6). Therapy was begun 4 days postinfection, and groups of 10 mice received either UR-9746, UR-9751, fluconazole (Pfizer, Groton, Conn.), 0.2% carboxymethyl cellulose-1% Tween 80 diluent, or no treatment. All drugs were delivered in the same diluent. UR-9746 and UR-9751 were given at 1, 10, or 100 mg/kg/day. Fluconazole was given at 10 or 100 mg/kg/day. Diluent controls were given an amount of diluent equivalent to that used in each dosage regimen. All treatments were by gavage once daily in a 0.1-ml volume on days 4 through 24 postinfection.
Deaths were tallied through 49 days postinfection, and all surviving mice were killed by CO 2 anoxia for quantitation of residual burdens of C. immitis in the spleen, liver, and lungs as described previously (4) (5) (6) . Statistical analyses of survival and of comparative burdens of C. immitis recovered from the organs of surviving mice were made by nonparametric Wilcoxon rank sums and Mann-Whitney U tests (10) .
Determination of the in vitro activities of UR-9746 and UR-9751 against the strain of C. immitis used to infect the mice showed that both drugs had some activity. The MIC and MFC of UR-9746 were 25 and Ͼ100 g/ml, the highest concentration tested, respectively. UR-9751 was somewhat more active, the MIC and MFC being 3.1 and Ͼ100 g/ml, respectively. In comparison, the MIC and MFC of fluconazole were 6.3 and Ͼ100 g/ml, respectively. Thus, on a microgram-per-milliliter basis UR-9751 is about twofold more active in vitro than fluconazole for inhibition and UR-9746 is about fourfold less active.
By bioassay, the pharmacokinetic data are expressed in terms of the native drug, though we do not at this time know the possible contribution to antifungal activity of metabolites. Peaks of bioactivity equivalent to 184 and 34 g/ml of UR-9746 and UR-9751, respectively, occurred at 8 and 8 to 24 h postdose (Fig. 2 ). There were then slow declines through 48 h postdose. The concentrations after chronic dosing of 100 mg/ kg were generally higher, and there appeared to be two peaks, the first 1 h after dosing and the second at 8 h (which was higher for UR-9746 than it was after a single dose). Some accumulation of bioactivity with UR-9746 after multiple dosing was apparent. The rate of decline after 24 h of bioactivity for both drugs appeared more rapid with multiple dosing. These curves might indicate a lessened first-pass effect of the native drug and more rapid metabolism of metabolites with prolonged multiple dosing. Most important, the half-life of bioactivity was Ͼ16 h for both drugs. Even after single doses, inhibitory concentrations Ն7-to 10-fold higher than the MICs of the native drugs for C. immitis were maintained for the entire interval between doses.
The results obtained in the in vivo model clearly demonstrate that all three drugs show dose-responsive efficacy against systemic coccidioidomycosis. Ninety percent of the control mice succumbed to infection, with all deaths occurring by day 18 (Fig. 3) . All drug regimens, except the 1-mg/kg/day UR-9746 or UR-9751 regimens, significantly prolonged survival over rates for both of the control groups (P Ͻ 0.01 to P Ͻ 0.001). All mice given the 10-or 100-mg/kg doses of UR-9746 or the 100-mg/kg dose of UR-9751 survived; 90% given UR-9751 at 10 mg/kg survived, and 80% given 100 mg of fluconazole per kg survived.
Statistical analysis of survival indicated that UR-9746 and UR-9751 were equivalent. On the basis of a milligram-perkilogram of body weight comparison, both UR-9746 and UR-9751 were Ն10-fold better than fluconazole in the prolongation of survival; 10 mg of either UR-9746 or UR-9751 per kg was better than 10 mg of fluconazole per kg (P Ͻ 0.001) and equivalent to 100 mg of fluconazole per kg (P Ͼ 0.05).
Further comparisons of activity were made based on the recovery of C. immitis from the organs of surviving mice. It should be noted that no mice treated with fluconazole, UR-9746, or UR-9751 were completely free of infection (i.e., no organisms recovered from the three organs examined). Thus, biological cure was not achieved at the dosages administered for any of the three drugs tested; three or fewer mice given the 100-mg/kg dose of either UR compound had no detectable infection in the spleen, and no other organs were free of infection (Table 1) . However, dose-responsive clearance of infection was observed (i.e., decreasing numbers of C. immitis organisms were recovered with increasing drug dosage) ( Table  1) .
Both UR-9746 and UR-9751 given at 100 mg/kg were superior to their 10-mg/kg doses in the reduction of infection in all three organs assayed (P Ͻ 0.001). UR-9746 was Ͼ10-fold better than fluconazole in the clearance of infection, with the 10-mg/kg dose of UR-9746 superior to the 100-mg/kg dose of fluconazole in all organs (P Ͻ 0.05). Similarly, UR-9751 was Ͼ10-fold more effective than fluconazole in the spleen and liver (P Ͻ 0.05 and P Ͻ 0.001, respectively). In the lungs, UR-9751 was superior to fluconazole at an equivalent 100-mg/kg dose (P Ͻ 0.001), and 10 mg of UR-9751 per kg was equivalent to 100 mg of fluconazole per kg. Preferential clearance of infection from organs was observed to a limited extent, with the spleen being more readily cleared than the liver or lungs (Table 1) .
In conclusion, UR-9746 and UR-9751 were found to be superior to fluconazole in the treatment of experimental systemic coccidioidomycosis. Both UR-9746 and UR-9751 lacked observable toxicity and were about 10-fold or more superior to fluconazole. However, it should be noted that administration of fluconazole on a twice-daily regimen might improve its efficacy. Even though UR-9751 was fourfold more active than UR-9746 in vitro (MIC of 6.3 versus 25, respectively), UR-9746 and UR-9751 were equivalent in overall efficacy in vivo. These results are encouraging, indicating that UR-9746 and/or UR-9751 should be tested further. a All groups consisted of 10 mice.
